Osteosarcoma, the most aggressive primary malignant bone tumor, has stagnant therapeutic outcomes despite decades of standard MAP chemotherapy and surgery; 5-year overall survival (OS) is
The intestinal immune system monitors the body’s largest interface with the environment. It must prevent adverse responses to ingested material, while protecting itself from harm, constraining the inflammatory potential of gut microbiota, and detecting…
Hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory disease caused by an overactivation of immune cells. Its low incidence and broad range of clinical signs and symptoms may mimic more common inflammatory and/or infectious processes, c…
Dry eye disease (DED) is increasingly prevalent among young individuals and often exhibits severe symptoms despite minimal structural damage, challenging the traditional structure–inflammation paradigm. We propose the concept of ocular “social jetlag,”…
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for malignant tumors such as advanced lung cancer, but their efficacy is limited. In recent years, the circadian rhythm has provided a brand-new optimization strategy for i…
Reverse vaccinology (RV) was originally conceived to leverage genomic information for antigen selection and promised a paradigm change in vaccine design. After a steady increment since 2000 and surge in 2021, RV-related publications have recently plate…
Emerging preclinical evidence challenges the long-standing assumption that Interleukin-1β (IL-1β) uniformly promotes non–small cell lung cancer (NSCLC). We show that, in the context of chemo-immunotherapy, IL-1β enhances anti-tumor immunity by inducing…
Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. For resectable early-stage NSCLC, surgery and adjuvant chemotherapy remain the standard treatments, but…
Based on the hypothesis that neovascularization was required for tumor growth, the search for angiogenesis inhibitors attracted considerable attention, leading to the development of the monoclonal antibody bevacizumab against vascular endothelial growt…
Diffuse podocytopathy (DP) is a clinical and pathological entity, which comprises minimal change disease and primary focal segmental glomerulosclerosis (FSGS). It is characterized by diffuse podocyte foot process effacement resulting in nephrotic syndr…
